Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

467 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Gene therapy using genome-edited iPS cells for targeting malignant glioma.
Tamura R, Miyoshi H, Imaizumi K, Yo M, Kase Y, Sato T, Sato M, Morimoto Y, Sampetrean O, Kohyama J, Shinozaki M, Miyawaki A, Yoshida K, Saya H, Okano H, Toda M. Tamura R, et al. Among authors: saya h. Bioeng Transl Med. 2022 Sep 10;8(5):e10406. doi: 10.1002/btm2.10406. eCollection 2023 Sep. Bioeng Transl Med. 2022. PMID: 37693056 Free PMC article.
5-Aminolevulinic acid increases boronophenylalanine uptake into glioma stem cells and may sensitize malignant glioma to boron neutron capture therapy.
Fukumura M, Nonoguchi N, Kawabata S, Hiramatsu R, Futamura G, Takeuchi K, Kanemitsu T, Takata T, Tanaka H, Suzuki M, Sampetrean O, Ikeda N, Kuroiwa T, Saya H, Nakano I, Wanibuchi M. Fukumura M, et al. Among authors: saya h. Sci Rep. 2023 Jun 22;13(1):10173. doi: 10.1038/s41598-023-37296-6. Sci Rep. 2023. PMID: 37349515 Free PMC article.
STNM01, the RNA oligonucleotide targeting carbohydrate sulfotransferase 15, as second-line therapy for chemotherapy-refractory patients with unresectable pancreatic cancer: An open label, phase I/IIa trial.
Fujisawa T, Tsuchiya T, Kato M, Mizuide M, Takakura K, Nishimura M, Kutsumi H, Matsuda Y, Arai T, Ryozawa S, Itoi T, Isayama H, Saya H, Yahagi N. Fujisawa T, et al. Among authors: saya h. EClinicalMedicine. 2022 Nov 17;55:101731. doi: 10.1016/j.eclinm.2022.101731. eCollection 2023 Jan. EClinicalMedicine. 2022. PMID: 36425867 Free PMC article.
Role of androgen signaling in androgen receptor-positive extramammary Paget's disease: Establishment of organoids and their biological analysis as a novel therapeutic target.
Nakamura Y, Mizukami H, Tanese K, Fusumae T, Hirai I, Amagai M, Takamatsu R, Nakamura K, Nishihara H, Takimoto T, Ueno M, Saya H, Funakoshi T. Nakamura Y, et al. Among authors: saya h. J Dermatol Sci. 2023 Oct;112(1):23-30. doi: 10.1016/j.jdermsci.2023.08.005. Epub 2023 Aug 29. J Dermatol Sci. 2023. PMID: 37661472
Potent neutralizing broad-spectrum antibody against SARS-CoV-2 generated from dual-antigen-specific B cells from convalescents.
Takeshita M, Fukuyama H, Kamada K, Matsumoto T, Makino-Okamura C, Lin Q, Sakuma M, Kawahara E, Yamazaki I, Uchikubo-Kamo T, Tomabechi Y, Hanada K, Hisano T, Moriyama S, Takahashi Y, Ito M, Imai M, Maemura T, Furusawa Y, Yamayoshi S, Kawaoka Y, Shirouzu M, Ishii M, Saya H, Kondo Y, Kaneko Y, Suzuki K, Fukunaga K, Takeuchi T; Keio Donner Project. Takeshita M, et al. Among authors: saya h. iScience. 2023 Jun 16;26(6):106955. doi: 10.1016/j.isci.2023.106955. Epub 2023 May 25. iScience. 2023. PMID: 37288342 Free PMC article.
Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models.
Takeshita M, Fukuyama H, Kamada K, Matsumoto T, Makino-Okamura C, Uchikubo-Kamo T, Tomabechi Y, Hanada K, Moriyama S, Takahashi Y, Ishigaki H, Nakayama M, Nguyen CT, Kitagawa Y, Itoh Y, Imai M, Maemura T, Furusawa Y, Ueki H, Iwatsuki-Horimoto K, Ito M, Yamayoshi S, Kawaoka Y, Shirouzu M, Ishii M, Saya H, Kondo Y, Kaneko Y, Suzuki K, Fukunaga K, Takeuchi T. Takeshita M, et al. Among authors: saya h. iScience. 2022 Dec 22;25(12):105596. doi: 10.1016/j.isci.2022.105596. Epub 2022 Nov 15. iScience. 2022. PMID: 36406861 Free PMC article.
467 results